According to the recent research report titled ‘Viscosupplementation Market Share, Size, Trends & Industry Analysis Report By Product; By Application; By Regions, Segment Forecast, 2020 – 2026’, available with Market Study Report, global viscosupplementation market is expected to amass a valuation of USD 6.9 billion during 2020-2026, registering a CAGR of 8.9% throughout.
 

The report states that global viscosupplementation market growth is driven by rising cases of injuries, osteoarthritis, abscess, and gingivitis, along with mounting aging population. As per World Health Organization (WHO), global population of people aged 65 and over has increased dramatically from 7% in 2000 and is expected to surge to 16% by 2050.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2963842/
 

Moreover, inclination towards minimally invasive surgical procedures and growing target population are also swaying the industry dynamics.
 

Based on product type, three injection segment is anticipated to hold a major market share, attributable to its short therapy duration and affordability.
 

Speaking of the geographical reach, North America held considerable portion of global viscosupplementation market share in 2019. About 30 million people in the United States suffered from osteo arthritis in 2015, and about 10% of people over 55 years suffered from knee pain, further boosting the product demand.
 

Meanwhile, Asia Pacific viscosupplementation industry witnessed tremendous growth in 2017 and is projected to grow substantially through 2026, creditable to booming elderly population susceptible to problems like rheumatoid joint inflammation and osteo arthritis.
 

Due to high unmet clinical demands, increasing disposable income, and rising recognition among patients in economies such as Brazil and Mexico, the Latin American market is expected to grow at a rewarding rate in the coming years.
 

The well-established firms operating in global viscosupplementation market are Seikagaku Corporation, Anika Therauptics Inc., Lifecore Biomedical LLC, Salix Pharmaceuticals Inc., Fidia Farmaceutici S.p.A., F. Hoffmann-La Roche AG, LG Lifesciences Ltd., Ferring B.V., Smith & Nephew Plc, Zimmer Biomet, and Sanofi S.A.